Shaping the future of Medicine
Leadership
Miguel Vega MEng, PDD-IESE
• Partner & General Manager.
• 25 Years of R&D and BD experience: Spanish National Genomic Foundation, UAM, European Commission.
• Former institutional investor in Sanifit, Genmedica, Bioncotech, VCN Biosciences and many others.
Diego Labarquilla MEng, MBA-Insead
• Partner & Business Advisor.
• President of Savera Group.
• Former corporate investor in Tigenix, recently acquired by Takeda.
Prof. Juan Gómez-Reino, MD
• Partner& Scientific Advisor.
• Former Head of Rheumatology at the University Hospital – Santiago de Compostela.
• 40 years of experience in clinical research.
• Former clinical advisor to top pharmaceutical companies.
Prof. Balbino Alarcón
• Partner & Scientific Advisor.
• Full Research Professor at the National Research Council (CSIC) – Madrid.
• 30 years of experience in R&D.
• Scientific advisor to Artax Biopharma.
Prof. Ángel Messeguer
• Partner & Scientific Advisor.
• Full Research Professor at the National Research Council (CSIC) – Barcelona.
• 40 years of experience in Medicinal Chemistry.
• Former scientific advisor to Menarini, Lipotec and Salvat.
Prof. Juan Jesús Pérez
• Chair Dept of Chemical Engineering, Polytechnic University of Catalonia – Barcelona.
• 30 years of experience in Computational Chemistry.
• Former scientific advisor to Ferrer, Menarini and Salvat.
Prof. Ignacio Torres Alemán
• Partner & Scientific Advisor.
• Full Research Professor at the National Research Council (CSIC) - Madrid
• 30 years of experience in R&D.
• Former scientific advisor to Takeda, Roche and Fonterra.
Team
Dept. of Computational Chemistry
- Accelerated Molecular Dynamics
- Ensemble docking and in silico drug screening
- NMR studies
- Protein crystallization studies
Patricia Gómez Ph.D.
- Head of Computational Chemistry
- 7 years experience in drug design and molecular modeling
Dept. of Molecular & Cell Biology
- Target validation, mutagenesis and purification
- in vitro and in vivo compound screening
- Animal efficacy studies
Pedro Campos Ph.D.
- Head of Molecular Biology
- 7 years experience in the biology of drug discovery
Dept. of Medicinal Chemistry
- Novel structure synthesis
- Site-directed combinatorial chemistry for lead optimization
Esther Carrasco Ph.D.
- Head of MedChem (inflammation)
- 9 years experience in Medicinal Chemistry
Asunción Burguete Ph.D.
- Head of MedChem (oncology)
- 7 years experience in Medicinal Chemistry
Publications
- A window of opportunity for cooperativity in the T Cell Receptor. Nat Commun 2018 Jul
- R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes. Sci Signal. 2018 May
- Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS One. 2018 May
- Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May
- The Allostery Model of TCR Regulation. J Immunol, 2017 Jan
- Identification of Potential Small Molecule Binding Pockets in p38α MAP Kinase. J Chem Inf Model, 2017 Sep
- Flavonoid allosteric modulation of mutated visual rhodopsin associated with retinitis pigmentosa. Sci Rep. 2017 Sep
- Insulin Regulates Astrocytic Glucose Handling Through Cooperation With IGF-I. Diabetes. 2017 Jan
- Identification of a Novel Inhibitory Allosteric Site in p38α. Plos One, 2016 Dec
- First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med, 2016 Dec
- Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability. Cell, 2016 Aug
- A Cholesterol-Based Allostery Model of T Cell Receptor Phosphorylation. Immunity, 2016 May
- Blockade of the Interaction of Calcineurin with FOXO in Astrocytes Protects Against Amyloid-β-Induced Neuronal Death. J Alzheimers Dis, 2016 Apr
- Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat Immunol, 2009 Jun
- Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell, 2008 May
- Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci, 2007 Oct
- Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis, 2014 May
- Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl Psychiatry, 2013 Dec
- Assessment of osteoarthritis candidate genes in a meta-analysis of 9 genome-wide association studies. Arthritis Rheum, 2013 Dec
- Reduced brain insulin-like growth factor I function during aging. Mol Cell Neurosci, 2012 Jan
- RRas2, RhoG and T-cell phagocytosis. Small GTPases, 2012 Apr
- The many faces of insulin-like signalling in the brain. Nat Rev Neurosci, 2012 Mar
- Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology. Mol Psychiatry, 2011 Oct
- Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease. Arthritis, 2011 Aug
- T cell receptor internalization from the immunological synapse is mediated by TC21 and RhoG GTPase-dependent phagocytosis. Immunity, 2011 Agu
- Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 834-46, 2010 Sep